Form 4: Krystal Biotech CEO Executes Planned Stock Sale

Krystal Biotech CEO Krish S. Krishnan sold 25,000 shares of common stock on June 4, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Summary

• CEO Krish S. Krishnan sold a total of 25,000 shares of Krystal Biotech common stock on June 4, 2026.
• The sales were executed at weighted average prices ranging from $300.75 to $312.23 per share.
• Following these transactions, the CEO retains direct ownership of 1,450,253 shares.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on September 4, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were pre-planned and represent a standard liquidity event for an executive.

Positives

• The sale was conducted via a pre-arranged Rule 10b5-1 plan, which is a standard mechanism for executives to sell stock without triggering insider trading concerns.
• The CEO maintains a significant remaining equity stake of over 1.45 million shares, signaling continued alignment with shareholder interests.

Negatives

• The transaction represents a reduction in the CEO's direct holdings of the company's common stock.

Risks

• The Rule 10b5-1 plan remains active until December 4, 2026, meaning further periodic sales may occur throughout the year.

Future Outlook

The filing indicates that the Rule 10b5-1 trading plan will continue until December 4, 2026, or until all shares subject to the plan are sold.

Management Comments

• The reporting person disclaims beneficial ownership of shares held by his spouse, except to the extent of his pecuniary interest.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine corporate governance events and generally do not reflect a change in management's outlook on the company's fundamental business performance.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives at major biotech firms like Vertex Pharmaceuticals or Regeneron to manage personal liquidity while maintaining regulatory compliance.

Related Party Transactions

• The reporting person notes that his spouse, Suma M. Krishnan, files separate reports regarding her own transactions and holdings.

Stakeholder Impact

• Minimal impact expected as the sales were pre-scheduled and represent a small portion of the CEO's total holdings.

Next Steps

• Continued execution of the Rule 10b5-1 trading plan through December 4, 2026.

Key Dates

Keywords

Krystal Biotech, KRYS, Insider Trading, Form 4, Krish S. Krishnan, Biotech, Rule 10b5-1